Prosecution Insights
Last updated: April 19, 2026
Application No. 17/751,474

PROTECTED TRIAZABUTADIENE COMPOSITIONS FOR CELLULAR STUDIES IN INTACT BIOLOGICAL SYSTEMS

Non-Final OA §112
Filed
May 23, 2022
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arizona Board of Regents
OA Round
2 (Non-Final)
78%
Grant Probability
Favorable
2-3
OA Rounds
2y 5m
To Grant
74%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
1410 granted / 1810 resolved
+17.9% vs TC avg
Minimal -3% lift
Without
With
+-3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
29 currently pending
Career history
1839
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
7.1%
-32.9% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
52.2%
+12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1810 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-6 and 8-16 are currently pending in the instant application. Applicants have amended claims 6, 8-10 and cancelled claim 7 in an amendment filed on November 6, 2025. Claims 6 and 8-10 are rejected and claims 1-5 and 11-16 are withdrawn from consideration in this Office Action. I. Response to Arguments Applicants’ amendment, filed on November 6, 2025, has overcome the rejection of claim 6 under 35 USC 112(b) as being indefinite because variables X, D, E, B, A and Y had not been defined in the claim; the rejection of claims 7-10 under 35 USC 112(b) as being indefinite for variable D being present in the definition of variable E and variable E being present in the definition of variable D; the objection of claims 6-10 for minor informalities. The above rejections and objection have been withdrawn. The Examiner wants to point out that the withdrawn claims 1-5 and 11-16 are not subject to rejoinder because these claims do not contain all of the limitations of the elected claims 6 and 8-10. Claims 1-5 and 11-16 are drawn to different and distinct inventions and will not be rejoined. Applicants are suggested to delete withdrawn claims 1-5 and 11-16 in response to this Office Action so that when all issues are resolved in the elected claims 6 and 8-10, these claims can be allowed. II. Rejection(s) Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 6 and 8-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, variable X is defined as the following: PNG media_image1.png 118 622 media_image1.png Greyscale Then K is defined as being “selected from a group consisting of….” but there is no “and” in between the last two options in the group so that it is clear where the group ends. As of now, the limitation reads “K is selected from a group consisting of sulfonate, phosphate or a quaternary ammonium cation” then it states “or an alkyl, aryl or propargylic containing moiety that can facilitate…”. The way that the claim is written it is unclear what is included in the definition of X and what is included in the definition of K. Therefore, the claims are considered indefinite. To overcome the rejection, Applicants are suggested to amend claim 6 to insert the term “and” in between the last two groups of variable X and/or K so that it is clear where each of the groups end of the variables. III. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is (571)272-9043. The examiner can normally be reached on M-F 7AM-4PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached on (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

May 23, 2022
Application Filed
Aug 09, 2025
Non-Final Rejection — §112
Nov 06, 2025
Response Filed
Mar 14, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600903
DELAYED FLUORESCENCE COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594265
METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3
2y 5m to grant Granted Apr 07, 2026
Patent 12595231
NOVEL CRYSTALLINE SALT FORMS OF MESEMBRINE
2y 5m to grant Granted Apr 07, 2026
Patent 12590047
METHOD FOR PRODUCING FLUORINE-CONTAINING OLEFIN
2y 5m to grant Granted Mar 31, 2026
Patent 12583818
NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
78%
Grant Probability
74%
With Interview (-3.4%)
2y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 1810 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month